What Does Gastroparesis Look Like in Ozempic Users?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Risk Awareness

If you're taking Ozempic and experiencing persistent nausea, bloating, or abdominal pain, you may wonder whether the medication is causing gastroparesis—a condition where stomach emptying is delayed. Building on decades of research into drug-induced gastrointestinal disorders, this page reviews the clinical evidence connecting Ozempic to gastroparesis and what diagnostic findings can show.

Ozempic and Gastroparesis: Pharmacological Link and Clinical Evidence

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in some formulations, for chronic weight management. Its mechanism of action includes slowing gastric emptying, which contributes to its therapeutic effects on glycemic control and satiety. However, this same pharmacological property has been associated with a range of gastrointestinal adverse reactions, including gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation and diagnosis of gastroparesis typically involve a history of persistent gastrointestinal symptoms, and confirmation often requires gastric emptying scintigraphy or other motility studies. The diagnosis is critical because the condition can significantly impair quality of life and lead to complications such as malnutrition, dehydration, and bezoar formation. In the context of Ozempic use, the link between the drug and gastroparesis is supported by the drug's known effect on gastric motility and the high incidence of gastrointestinal adverse events reported in clinical trials. According to the prescribing information for Ozempic, gastrointestinal adverse reactions occurred more frequently among patients receiving the drug compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, other gastrointestinal adverse reactions with a frequency of less than 5% were associated with Ozempic, including dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data underscore the potential for significant gastrointestinal morbidity, including gastroparesis, in patients using Ozempic.

Mechanistic Pathways and Warning Adequacy

The mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors in the gastrointestinal tract, which slows gastric emptying. While this effect is intended to improve glycemic control, it can become pathological in some individuals, leading to symptomatic delayed gastric emptying. The risk may be heightened during dose escalation, as the gastrointestinal system adapts to the drug. Furthermore, the prescribing information does not explicitly list gastroparesis as a warning or precaution, though it does include warnings for hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The adequacy of warnings regarding Ozempic and gastroparesis is a key consideration for affected patients. The label's focus on nausea, vomiting, and diarrhea may not fully alert patients and healthcare providers to the risk of developing gastroparesis, a more severe and chronic condition. This gap in risk communication could be relevant in legal contexts, such as settlement considerations for patients who have suffered harm.

Statute of Limitations for Ozempic Claims in Florida

For patients in Florida considering legal action related to Ozempic-associated gastroparesis, the statute of limitations is a critical factor. In Florida, the statute of limitations for personal injury claims, including product liability and failure-to-warn cases, is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline is crucial because gastroparesis may develop insidiously, and the connection to Ozempic use might not be immediately apparent. The timeline between exposure to Ozempic and documented harm can vary widely. Some patients may experience symptoms during dose escalation, while others may develop gastroparesis after months or years of use. Medical records documenting the onset of symptoms, diagnostic tests confirming gastroparesis, and the temporal relationship to Ozempic use are essential for establishing a claim. Settlement-related considerations for affected patients include the strength of the evidence linking Ozempic to their condition, the adequacy of the drug's warnings, and the extent of harm suffered. Patients should consult with a qualified attorney experienced in pharmaceutical litigation to evaluate their case. The evidence from clinical trials showing a higher incidence of gastrointestinal adverse events with Ozempic compared to placebo, along with the drug's known effect on gastric emptying, provides a foundation for claims that the manufacturer failed to adequately warn about the risk of gastroparesis. However, each case must be assessed individually, considering factors such as the patient's medical history, the duration of Ozempic use, and the presence of other potential causes of gastroparesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Florida?

In Florida, the statute of limitations for personal injury claims, including product liability and failure-to-warn cases related to Ozempic, is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. It is important to act promptly after diagnosis to preserve legal rights.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism of action. In some individuals, this effect can become pathological, leading to symptomatic delayed gastric emptying consistent with gastroparesis. Clinical trial data show a higher incidence of gastrointestinal adverse events with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.